SF3B1 and myelodysplastic syndrome: In various other cancers, notably myelodysplastic syndrome (MDS; 25–30%) (5–7) and uveal melanoma (UM; 10–21%) (8–10), heterozygous SF3B1 mutations are also highly prevalent.